LMB-2 to Treat Hairy Cell Leukemia
Hairy Cell Leukemia
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Hairy cell leukemia is highly treatable but rarely cured. Because it is easily controlled, many patients have prolonged survival with the use of sequential therapies. The decision to treat is based on signs of disease progression, including any of the following factors:
Cytopenias (especially if symptomatic).
Increasing splenomegaly.
The presence of other, usually infectious, complications.
If the patient is asymptomatic and if blood counts are maintained in an acceptable range, therapy may not be needed.[1]
Sources: 1
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Prior to the COVID-19 (SARS-CoV-2) pandemic, the standard initial therapy for patients with hairy cell leukemia was infusion of cladribine daily for 5 days, given with or without eight weekly doses of rituximab.[2-4] However, treatment with a purine analogue–based regimen led to significant and prolonged neutropenia and impairment of T-cell function, which were both problematic during the pandemic in fighting viral infection and establishing vaccination-induced immunity.
Other options for initial standard therapy, instead of cladribine or pentostatin, may offer less toxicity in terms of infection and long-term risk of secondary malignancies. However, these options may provide less durable response.
The Hairy Cell Leukemia Foundation convened a virtual meeting of 39 experts from around the world to amend the 2017 consensus recommendations.[5] The adapted treatment guidelines, published in 2021, are based primarily on anecdotal experience and expert opinion, as controlled trials for this indolent leukemia cannot be completed expeditiously given the low incidence of this disease.[6][Level of evidence C3] The adapted treatment guidelines are summarized below.
Sources: 5 · 6 · Level of evidence C3
Consider watchful waiting when feasible; asymptomatic patients with noncritical levels of pancytopenia can be monitored closely.
Cladribine, with or without rituximab,[4] remains the standard of care. However, due to the risk of serious and prolonged immunosuppression, nonchemotherapy treatment options may be preferable for older, frail patients with higher risk of infection (or for those who have active infections).
Sources: 4
BRAF inhibitors such as vemurafenib, dabrafenib, or encorafenib are nonchemotherapeutic options that can be combined with rituximab or obinutuzumab.[7-10] Most patients with hairy cell leukemia have BRAF pathogenic variants, but this should be verified by flow cytometry. Despite extensive experience with vemurafenib for patients with relapsed disease, the U.S. Food and Drug Administration (FDA) has not approved oral vemurafenib for patients with hairy cell leukemia.
Consider using rituximab alone intravenously (IV) for 4 to 8 weeks or in combination with a BRAF inhibitor.[11] Anti-CD20 monoclonal antibodies can impair future vaccine response, but they do not affect immunity from prior vaccination.
Sources: 11
In patients with relapsed disease, the previously mentioned options are available, along with ibrutinib (the Bruton tyrosine kinase inhibitor).[12]
Sources: 12
Treatment options for hairy cell leukemia include:
Watchful waiting, if feasible.
Cladribine with or without rituximab.
Sources: Cladribine with or without rituximab
BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib.
Sources: BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib
Rituximab.
Sources: Rituximab
Pentostatin.
Sources: Pentostatin
Ibrutinib.
Sources: Ibrutinib
Re-treatment with cladribine or pentostatin.
Bendamustine with rituximab.
Sources: Bendamustine with rituximab
Splenectomy.
Sources: Splenectomy
Interferon.
Sources: Interferon
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Cladribine may be given with or without rituximab to treat hairy cell leukemia.
Evidence (cladribine with or without rituximab):
In a phase II study, 68 patients with previously untreated hairy cell leukemia were randomly assigned to receive cladribine (0.15 mg/kg IV) on days 1 to 5, with eight weekly doses of rituximab either concurrently (starting on day 1) or delayed (starting after 6 months of cladribine treatment) if still positive with measurable residual disease (MRD) testing.[4][Level of evidence C3]
Sources: 4 · Level of evidence C3
In a phase II study, 68 patients with previously untreated hairy cell leukemia were randomly assigned to receive cladribine (0.15 mg/kg IV) on days 1 to 5, with eight weekly doses of rituximab either concurrently (starting on day 1) or delayed (starting after 6 months of cladribine treatment) if still positive with measurable residual disease (MRD) testing.[4][Level of evidence C3]
With a median follow-up of 96 months, 94% of patients who received concurrent therapy were MRD-free, compared with 12% of patients who received delayed therapy.
Although patients who underwent concurrent therapy had more need for platelet transfusions, they demonstrated higher neutrophil and platelet counts after 1 month.
A retrospective case series reported a median progression-free survival (PFS) of 67 months in patients with relapsed disease who received a purine nucleoside analogue (usually cladribine) plus rituximab.[13][Level of evidence C2]
Sources: 13 · Level of evidence C2
A retrospective case series of nine patients with a histologic variation of hairy cell leukemia (HCL-v) reported an 88% complete response rate and 3-year PFS rate of 42% (95% confidence interval [CI], 1%–84%) after treatment with a purine nucleoside analogue (usually cladribine) plus rituximab.[14][Level of evidence C2]
Sources: 14 · Level of evidence C2
Cladribine was given by daily subcutaneous injections or by daily 2-hour IV infusions for 5 to 7 days.[5,15-17][Level of evidence C3] Purine analogues should be avoided in cases of active infection or moderate to severe hepatic or renal impairment.
Sources: 5 · 15 · 17 · Level of evidence C3
Cladribine was given by daily subcutaneous injections or by daily 2-hour IV infusions for 5 to 7 days.[5,15-17][Level of evidence C3] Purine analogues should be avoided in cases of active infection or moderate to severe hepatic or renal impairment.
The complete response rate was 50% to 80%.
The overall response rate was 85% to 95%.
A National Cancer Institute group C protocol of 979 patients treated with cladribine reported lower response rates (i.e., 50% complete remission rate, 37% partial remission rate) compared with other studies.[18] Responses were durable in patients treated with a short course of cladribine, and patients who had a relapse often responded to re-treatment with cladribine.[2,13,19]
A retrospective review included 83 patients, aged 40 years and younger.[2]
Sources: 2
A retrospective review included 83 patients, aged 40 years and younger.[2]
The median time to first relapse was 54 months for all responders, and the median overall survival (OS) was 21 years from diagnosis.
Cladribine may cause fever and immunosuppression; documented infection was found in 33% of treated patients.
In a retrospective study of patients with cladribine-associated neutropenic fever, filgrastim (G-CSF) did not reduce the percentage of febrile patients, number of febrile days, or frequency of hospital admissions to receive antibiotics.[3]
Sources: 3
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
BRAF V600E pathogenic variants are found in almost 100% of patients with classic-form hairy cell leukemia and almost never found in patients with other B-cell lymphomas and leukemias, including HCL-v.[20][Level of evidence C3] Vemurafenib or other BRAF inhibitors such as dabrafenib can be given with rituximab or obinutuzumab.[10,21] The FDA has not approved BRAF inhibitors for hairy cell leukemia, but they can be used off-label in clinical practice.[22]
Sources: 20 · Level of evidence C3 · 10 · 21 · 22
Evidence (vemurafenib with or without rituximab):
Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3]
Sources: 7 · 8 · 10 · 23 · Level of evidence C3
Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3]
After a median follow-up of 23 to 40 months, for the 86 patients treated with vemurafenib alone, the following was reported in two studies:[7,8,23][Level of evidence C3]
Sources: 7 · 8 · 23 · Level of evidence C3
Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3] › After a median follow-up of 23 to 40 months, for the 86 patients treated with vemurafenib alone, the following was reported in two studies:[7,8,23][Level of evidence C3]
The overall response rate was 86% to 98%.
The complete response rate was 33% to 38%.
The median treatment-free survival was 18 to 25 months.
Retreatment at relapse resulted in an 86% response rate, and the median relapse-free survival was 12.7 months in one of the trials, with a 40-month median follow-up.[23][Level of evidence C2]
Sources: 23 · Level of evidence C2
Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3]
After a median follow-up of 37 months, for the 30 patients treated with vemurafenib plus rituximab, the following was reported:[10][Level of evidence C3]
Sources: 10 · Level of evidence C3
Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3] › After a median follow-up of 37 months, for the 30 patients treated with vemurafenib plus rituximab, the following was reported:[10][Level of evidence C3]
The complete response rate was 87%.
The PFS rate was 78% at 37 months.
In patients who had a complete response, 65% had no MRD.
Evidence (dabrafenib plus trametinib):
In a phase II trial of patients with relapsed or refractory disease, 55 patients received dabrafenib and trametinib orally until their disease progressed, they experienced unacceptable toxicity, or death occurred.[24]
Sources: 24
In a phase II trial of patients with relapsed or refractory disease, 55 patients received dabrafenib and trametinib orally until their disease progressed, they experienced unacceptable toxicity, or death occurred.[24]
With a median follow-up of 43.2 months, the overall response rate was 89.0% (95% CI, 77.8%–95.9%), the complete response rate was 65.5%, the 2-year PFS rate was 94.5%, and the 2-year OS rate was 95.5%.[24][Level of evidence C1]
Sources: 24 · Level of evidence C1
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Rituximab can induce durable remissions (with minimal toxic effects), but rarely complete remissions, in patients with multiple relapses or refractory disease after treatment with a purine analogue or interferon.[11,22,25][Level of evidence C3]
Sources: 11 · 22 · 25 · Level of evidence C3
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Pentostatin given IV every other week for 3 to 6 months produced a 50% to 76% complete response rate and an 80% to 87% overall response rate.[26] Complete remissions were of substantial duration. Purine analogues should be avoided in cases of active infection or moderate to severe hepatic or renal impairment.
Sources: 26
Evidence (pentostatin):
Two trials reported results on the 9-year median follow-up of patients treated with pentostatin.[27,28]
Two trials reported results on the 9-year median follow-up of patients treated with pentostatin.[27,28]
The relapse-free survival rates ranged from 56% to 67%.
Side effects included fever, immunosuppression, cytopenias, and renal dysfunction.
A randomized trial compared pentostatin to recombinant interferon alfa-2a.[26]
Sources: 26
A randomized trial compared pentostatin to recombinant interferon alfa-2a.[26]
Pentostatin demonstrated higher response rates and more durable responses.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Ibrutinib, a tyrosine kinase inhibitor, has been studied in the treatment of hairy cell leukemia.
Evidence (ibrutinib):
In a phase II study, 37 patients with refractory hairy cell leukemia were treated with ibrutinib. The median follow-up was 42 months.[29][Level of evidence C3]
Sources: 29 · Level of evidence C3
In a phase II study, 37 patients with refractory hairy cell leukemia were treated with ibrutinib. The median follow-up was 42 months.[29][Level of evidence C3]
The response rate was 54%.
The estimated 36-month PFS rate was 73%.
The OS rate was 85%.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Patients with hairy cell leukemia who have a relapse after the first course of cladribine or pentostatin often respond well to re-treatment with the same or another purine analogue, especially if relapse occurs after several years.[13][Level of evidence C3]
Sources: 13 · Level of evidence C3
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Evidence (bendamustine with rituximab):
A phase II study evaluated 12 patients with relapsed or refractory disease, three of whom were negative for BRAF variants. Patients received the combination of bendamustine and rituximab.[30]
Sources: 30
A phase II study evaluated 12 patients with relapsed or refractory disease, three of whom were negative for BRAF variants. Patients received the combination of bendamustine and rituximab.[30]
The overall response rate was 100%, and the complete remission rate was 50%.[30][Level of evidence C3]
Sources: 30 · Level of evidence C3
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Splenectomy plays a decreasing role in treating hairy cell leukemia because effective alternatives are available. Splenectomy will partially or completely normalize the peripheral blood in most patients with hairy cell leukemia.[31] After a splenectomy, there is usually little or no change in the bone marrow, and virtually all patients have progressive disease within 12 to 18 months.
Sources: 31
Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025. Captured 2026-09-09.
Interferon alfa is no longer available because production has been halted.[32] According to the Hairy Cell Leukemia Foundation, ropeginterferon alfa-2b-njft is the best available preparation, but it is not FDA approved for hairy cell leukemia.
Sources: 32
Interferon is useful when treating hairy cell leukemia during pregnancy because it does not involve cytotoxic agents.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
The treatment options depend on:
The number of hairy (leukemia) cells and healthy blood cells in the blood and bone marrow.
Whether the spleen is swollen.
Whether there are signs or symptoms of leukemia, such as infection.
Whether the leukemia has recurred (come back) after previous treatment.
Sources: recurred
The prognosis depends on:
Sources: prognosis
Whether the hairy cell leukemia does not grow or grows so slowly it does not need treatment.
Whether the hairy cell leukemia responds to treatment.
Sources: responds
Treatment often results in a long-lasting remission (a period during which some or all of the signs and symptoms of the leukemia are gone). If the leukemia returns after it has been in remission, re-treatment often causes another remission.
Sources: remission
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Refractory hairy cell leukemia is cancer that does not respond to treatment.
Sources: Refractory · respond
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
There are different types of treatment for patients with hairy cell leukemia.
The following types of treatment are used:
The following types of treatment are used:
Watchful waiting
Chemotherapy
Targeted therapy
Surgery
New types of treatment are being tested in clinical trials.
Treatment for hairy cell leukemia may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up care may be needed.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Different types of treatment are available for patients with hairy cell leukemia. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: hairy cell leukemia · standard · clinical trials · research study · cancer
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Watchful waiting is closely monitoring a patient's condition, without giving any treatment until signs or symptoms appear or change.
Sources: Watchful waiting · signs · symptoms
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). The way the chemotherapy is given depends on the type and stage of the cancer being treated. Cladribine and pentostatin are anticancer drugs commonly used to treat hairy cell leukemia. These drugs may increase the risk of other types of cancer, especially Hodgkin lymphoma and non-Hodgkin lymphoma. Long-term follow-up for second cancers is very important. Bendamustine is another anticancer drug that is being studied to treat hairy cell leukemia.
Sources: Chemotherapy · drugs · injected · vein · systemic chemotherapy · stage · Cladribine · pentostatin · Hodgkin lymphoma · non-Hodgkin lymphoma · follow-up · second cancers · Bendamustine
Learn more about Drugs Approved for Hairy Cell Leukemia.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.
Sources: Targeted therapy
Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Rituximab is a type of monoclonal antibody that may be used to treat certain patients with hairy cell leukemia.
Sources: Monoclonal antibody · proteins · antibodies · infusion · toxins · radioactive · Rituximab
Other types of targeted therapies are being studied in the treatment of hairy cell leukemia, including:
Vemurafenib, dabrafenib, and trametinib are types of kinase inhibitors that block certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing.
Sources: Vemurafenib · dabrafenib · trametinib · mutated · BRAF
Ibrutinib is a type of targeted therapy that blocks a protein called Bruton's tyrosine kinase (BTK), which may help keep cancer cells from growing.
Sources: Ibrutinib
Learn more about Drugs Approved for Hairy Cell Leukemia.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Splenectomy is a surgical procedure to remove the spleen.
Sources: Splenectomy · spleen
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 23, 2025. Captured 2026-09-09.
Treatment of hairy cell leukemia may include:
Sources: hairy cell leukemia
Watchful waiting when possible.
Sources: Watchful waiting
Cladribine with or without rituximab.
Sources: Cladribine · rituximab
BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib.
Sources: vemurafenib · dabrafenib · trametinib
Rituximab.
Pentostatin.
Sources: Pentostatin
Ibrutinib.
Sources: Ibrutinib
Repeat treatment with cladribine or pentostatin.
Bendamustine with rituximab.
Sources: Bendamustine
Splenectomy.
Sources: Splenectomy
Learn more about these treatments in the Treatment Option Overview
Sources: Treatment Option Overview
You and your doctor will discuss what treatment plan is best for you.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Hairy Cell Leukemia
ClinicalTrials.gov recordHairy Cell Leukemia
ClinicalTrials.gov recordHairy Cell Leukemia
ClinicalTrials.gov recordHairy Cell Leukemia
ClinicalTrials.gov recordHairy Cell Leukemia
ClinicalTrials.gov recordHairy Cell Leukemia
ClinicalTrials.gov recordLeukemia, Hairy Cell
ClinicalTrials.gov recordFollicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia,...
ClinicalTrials.gov recordAnemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma,...
ClinicalTrials.gov recordHairy Cell Leukemia
ClinicalTrials.gov recordRelapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma, Relapsed/Refractory Hairy Cell Leukemia
ClinicalTrials.gov recordHairy Cell Leukemia
INDICATIONS AND USAGE NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia,...
DailyMed label